SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4.
Deysi Viviana Tenazoa WongHelder Veras Ribeiro-FilhoCarlos Wagner Souza WanderleyCaio Abner Vitorino Gonçalves LeiteJonilson Berlink LimaAlexia Nathália Brígido AssefAurilene Gomes CajadoGabriela Loiola Ponte BatistaRafael Holanda GonzálezKarla Oliveira SilvaLuis Philipi Carvalho BorgesNylane Maria Nunes AlencarDiego Veras WilkeThiago Mattar CunhaAna Carolina Migliorini FigueiraFernando Queiroz CunhaRoberto Cesar Pereira Lima-JúniorPublished in: Cancer chemotherapy and pharmacology (2019)
Therefore, SN-38 inhibits acute inflammation by blocking LPS-driven TLR4 signaling. This mechanism seems to be shared by other Top I inhibitors.